AFP and hepatocellular carcinoma: Considering that NTN4 was altered even in AFP-negative HCCs, it is indicative of the usefulness of NTN4 as a biomarker in the AFP-negative HCC subgroup, which may also serve as a solution to circumvent the moderate levels of sensitivity and specificity of AFP.